Alphamab at 20-month high after FDA support for cancer drug

Alphamab Oncology

29/07/2025 04:35

** Shares of Alphamab Oncology 9966.HK rise 5.4% to HK$9.72, their highest level since Nov 2023

** Stock set for second session of gains

** Chinese biopharmaceutical company says U.S. FDA grants its JSKN003 the Orphan Drug Designation for treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ)

** Says GC/GEJ is fifth most common cancer and the fifth leading cause of cancer death worldwide

** Designation allows JSKN003 to obtain relevant policy supports for subsequent R&D, registration and commercialisation in the U.S. and, upon approval, the potential for seven years of U.S. market exclusivity.

** Hang Seng Biotech Index .HSHKBIO surges 2.8%, while benchmark Hang Seng Index .HSI slips 0.9%

** YTD, stock up 166.9%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))